biotech · Locally Advanced Breast Cancer (LABC) · Mantle Cell Lymphoma
Beijing Luzhu Biopharmaceutical
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Beijing Luzhu Biopharmaceutical clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Beijing, CN
- Employees
- 2
- Programs
- 7
- Drugs
- 5
- Patents
- 0
Beijing Luzhu Biopharmaceutical projects
7 ClinicalTrials.gov programs sponsored by Beijing Luzhu Biopharmaceutical.
Beijing Luzhu Biopharmaceutical has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
MCV-ACYW135 Vaccine Group
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Meningitis
1 trial -
pneumococcal disease prevention
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Vaccines
1 trial -
ICP-022
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Mantle Cell Lymphoma
1 trial -
ICP-022
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Systemic Lupus Erythematosus
1 trial -
BioTTT001 injection
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Locally Advanced Breast Cancer (LABC)
1 trial -
Vagus Nerve Stimulation
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Refractory Epilepsy
1 trial -
YN001
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Cardiovascular Diseases
1 trial
Frequently asked questions
How many clinical projects does Beijing Luzhu Biopharmaceutical have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.